ReviewJournal of personalized medicine2023
Lung and Gut Microbiome in COPD.
Review in Journal of personalized medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Profiling of human lung and gut microbiomes in different conditions of chronic obstructive pulmonary disease using ontology-based evidence synthesis and reasoning.Frontiers in cellular and infection microbiology · 2026Pooled it
- Characteristics of Respiratory Microbiome in COPD-A Literature Review.Advances in respiratory medicine · 2026Review
- Distinct gut microbiome signatures associated with sedentary behavior improvement following rehabilitation in chronic obstructive pulmonary disease patients with higher functional exercise capacity.Scientific reports · 2026Article
- Article
- Targeting the gut-lung axis in COPD: from microbial metabolites to fecal microbiota transplantation.Frontiers in microbiology · 2026Review
- Analysis of Respiratory Microbiota Characteristics in Patients with COPD and High-Risk Populations Using 16S rRNA Technology.International journal of chronic obstructive pulmonary disease · 2026Article
- Research Advances on the Impact of Gut Microbiota on COPD: Exploring New Perspectives on the Microbiota-Gut-Lung Axis.Current microbiology · 2025Review
- The intersection between human metapneumovirus and the respiratory microbiome.Virology journal · 2025Review
- The silent microbial shift: climate change amplifies pathogen evolution, microbiome dysbiosis, and antimicrobial resistance.Tropical diseases, travel medicine and vaccines · 2025Review
- RSV infection disrupts gut microbiota and metabolic homeostasis in mice, regulating pulmonary inflammation via the SPHK/S1P pathway.Microbiology spectrum · 2025Article
- Gut microbiota and SCFAs improve the treatment efficacy of chemotherapy and immunotherapy in NSCLC.NPJ biofilms and microbiomes · 2025Article
- The Role of Inflammation in the Pathogenesis of Comorbidity of Chronic Obstructive Pulmonary Disease and Pulmonary Tuberculosis.International journal of molecular sciences · 2025Review
- Lung cancer and the Gut-microbiota-lung Axis: emerging evidence and potential clinical implications.Frontiers in medicine · 2025Review
- Microbiome profiling reveals gut bacterial species associated with rapid lung function decline in people with HIV.Frontiers in immunology · 2025Article
- Chronic obstructive pulmonary disease: in-depth analysis of microbiota association and innovative prevention and treatment approaches from the gut-lung axis perspective.Frontiers in immunology · 2025Review
- Integrative network pharmacology, transcriptomics, and microbiomics elucidate the therapeutic mechanism ofFrontiers in microbiology · 2025Article
- Changes in the Gut Microbiome is Influenced by the Level of Control and Treatment in Asthma.Journal of asthma and allergy · 2025Article
- Lung Microbiome in Lung Cancer: A Systematic Review.Microorganisms · 2024Review
- Gut Microbiota Modulation in the Management of Chronic Obstructive Pulmonary Disease: A Literature Review.Cureus · 2024Review
- Deciphering the impact of microbial interactions on COPD exacerbation: An in-depth analysis of the lung microbiome.Heliyon · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death worldwide. The association between lung and gut microbiomes in the pathogenesis of COPD has been recently uncovered. The goal of this study was to discuss the role of the lung and gut microbiomes in COPD pathophysiology. A systematic search of the PubMed database for relevant articles submitted up to June 2022 was performed. We examined the association between the lung and gut microbiome dysbiosis, reflected in bronchoalveolar lavage (BAL), lung tissue, sputum, and feces samples, and the pathogenesis and progression of COPD. It is evident that the lung and gut microbiomes affect each other and both play a vital role in the pathogenesis of COPD. However, more research needs to be carried out to find the exact associations between microbiome diversity and COPD pathophysiology and exacerbation genesis. Another field that research should focus on is the impact of treatment interventions targeting the human microbiome in preventing COPD genesis and progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.